Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of EV71-CA16 Bivalent Vaccine in People Aged 6 Months to 59 Years
NCT07326878Phase 1Not yet recruiting
- Sponsor
- Institute of Medical Biology
- Start
- Dec 2025
- Primary completion
- Aug 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of enterovirus type 71 + coxsackievirus type A16 bivalent inactivated vaccine (human diploid cell) in HIV-associated central nervous system involvement (HAND) (4 arms), sponsored by Institute of Medical Biology. Primary endpoint: Incidence of adverse events. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
enterovirus type 71 + coxsackievirus type A16 bivalent inactivated vaccine (human diploid cell)
03
Conditions
HIV-associated central nervous system involvement (HAND)
Beyond the preview
Go deeper on NCT07326878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07326878.